Skip to main content
Fig. 3 | Cardiovascular Diabetology

Fig. 3

From: Cardiovascular risk reduction with once-weekly semaglutide in subjects with type 2 diabetes: a post hoc analysis of gender, age, and baseline CV risk profile in the SUSTAIN 6 trial

Fig. 3

Time from baseline to first confirmed MACE in SUSTAIN 6. In subjects with a prior MI/stroke (a) vs no prior MI/stroke (b) (p = 0.75 for interaction) and in subjects with established CVD (c) vs CV risk factors only (including CKD) (p = 0.22 for interaction) (d). Kaplan–Meier estimates: Cox proportional hazards models of time from randomization to first EAC-confirmed MACE in the full analysis set, and treatment by subgroup interaction, if applicable, as fixed factor(s). Data were pooled for semaglutide groups and placebo groups, respectively. CI confidence interval, CKD chronic kidney disease, CV cardiovascular, CVD cardiovascular disease, EAC event adjudication committee, HR hazard ratio, MACE major adverse cardiovascular event, MI myocardial infarction

Back to article page